MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

MLA

David S. Siegel, et al. “MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 Mg/M2 and Once-Weekly at 70 Mg/M2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS Studies.” Clinical Lymphoma Myeloma and Leukemia, vol. 20, Sept. 2020, p. S288. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........2631a8d4881cd42a259e2d14a72cc31b&authtype=sso&custid=ns315887.

APA

David S. Siegel, Meral Beksac, Ming Qi, Ajai Chari, Sung-Soo Yoon, Takaaki Chou, Henry Miles Prince, Meletios A. Dimopoulos, Xavier Leleu, Tatiana Shelekhova, Ludek Pour, Albert Oriol, Mihaela Obreja, & Monica Khurana. (2020). MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies. Clinical Lymphoma Myeloma and Leukemia, 20, S288.

Chicago

David S. Siegel, Meral Beksac, Ming Qi, Ajai Chari, Sung-Soo Yoon, Takaaki Chou, Henry Miles Prince, et al. 2020. “MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 Mg/M2 and Once-Weekly at 70 Mg/M2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS Studies.” Clinical Lymphoma Myeloma and Leukemia 20 (September): S288. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........2631a8d4881cd42a259e2d14a72cc31b&authtype=sso&custid=ns315887.